Top

Published in:

01-09-2016 | Pictorial Essay

Clinical implications for imaging of vascular invasion in hepatocellular carcinoma

Authors: Akshay D. Baheti, Gregor M. Dunham, Christopher R. Ingraham, Mariam Moshiri, Chandana Lall, James O. Park, David Li, Douglas S. Katz, David C. Madoff, Puneet Bhargava

Published in: Abdominal Radiology | Issue 9/2016

Abstract

Hepatocellular carcinoma (HCC) is the second largest cause of cancer mortality in the world, with vascular invasion being one of the most important prognostic factors. HCC with tumor thrombus was traditionally considered to have very limited treatment options. However, multiple promising treatment strategies have emerged in recent years, with diagnostic and interventional radiologists playing a major role in patient management. We provide a comprehensive update on the diagnosis and management of HCC with vascular invasion and the role of the radiologist in this condition.

Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon: International Agency for Research on Cancer; 2013, accessed on 8/22/2015. Available from: http://globocan.iarc.fr

Surveillance, Epidemiology, and End Results (SEER) Program. [7.12.2015]. Available from: http://seer.cancer.gov/statfacts/html/livibd.html.

Manghisi G, Elba S, Mossa A, et al. (1998) A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28:751–755

Cabibbo G, Enea M, Attanasio M, et al. (2010) A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 51:1274–1283CrossRefPubMed

Greten TF, Papendorf F, Bleck JS, et al. (2005) Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer 92:1862–1868CrossRefPubMedPubMedCentral

Griffin N, Addley H, Sala E, et al. (2012) Vascular invasion in hepatocellular carcinoma: is there a correlation with MRI? Br J Radiol 85:736–744CrossRefPubMedPubMedCentral

Thuluvath PJ (2009) Vascular invasion is the most important predictor of survival in HCC, but how do we find it? J Clin Gastroenterol 43:101–102CrossRefPubMed

Du M, Chen L, Zhao J, et al. (2014) Microvascular invasion (MVI) is a poorer prognostic predictor for small hepatocellular carcinoma. BMC Cancer 14:14–38CrossRef

Subramaniam S, Kelley RK, Venook AP (2013) A review of hepatocellular carcinoma (HCC) staging systems. Chin Clin Oncol 2:33–41PubMed

10.

Chapiro J, Geschwind JF (2014) Hepatocellular carcinoma: have we finally found the ultimate staging system for HCC? Nat Rev Gastroenterol Hepatol 11:334–336CrossRefPubMed

11.

Yau T, Tang VY, Yao TJ, et al. (2014) Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 146(1691–700):e3PubMed

12.

Liccioni A, Reig M, Bruix J (2014) Treatment of hepatocellular carcinoma. Dig Dis 32:554–563CrossRefPubMed

13.

Sandrasegaran K, Tahir B, Nutakki K, et al. (2013) Usefulness of conventional MRI sequences and diffusion-weighted imaging in differentiating malignant from benign portal vein thrombus in cirrhotic patients. AJR Am J Roentgenol 201:1211–1219CrossRefPubMed

14.

Roayaie S, Jibara G, Taouli B, Schwartz M (2013) Resection of hepatocellular carcinoma with macroscopic vascular invasion. Ann Surg Oncol 20:3754–3760CrossRefPubMed

15.

Bruix J, Raoul JL, Sherman M, et al. (2012) Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 57:821–829CrossRefPubMed

16.

Tsai TJ, Chau GY, Lui WY, et al. (2000) Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery 127:603–608CrossRefPubMed

17.

Roayaie S, Blume IN, Thung SN, et al. (2009) A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology 137:850–855CrossRefPubMedPubMedCentral

18.

Maida M, Orlando E, Camma C, Cabibbo G (2014) Staging systems of hepatocellular carcinoma: a review of literature. World J Gastroenterol 20:4141–4150CrossRefPubMedPubMedCentral

19.

Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022CrossRefPubMedPubMedCentral

20.

Llovet JM, Fuster J, Bruix J (2004) Barcelona-Clinic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 10:S115–S120CrossRefPubMed

21.

Keating GM, Santoro A (2009) Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 69:223–240CrossRefPubMed

22.

Zhao Y, Cai G, Zhou L, et al. (2013) Transarterial chemoembolization in hepatocellular carcinoma with vascular invasion or extrahepatic metastasis: a systematic review. Asia Pac J Clin Oncol 9:357–364CrossRefPubMed

23.

Raab BW (2005) The thread and streak sign. Radiology 236:284–285CrossRefPubMed

24.

Rossi S, Ghittoni G, Ravetta V, et al. (2008) Contrast-enhanced ultrasonography and spiral computed tomography in the detection and characterization of portal vein thrombosis complicating hepatocellular carcinoma. Eur Radiol 18:1749–1756CrossRefPubMed

25.

Rossi S, Rosa L, Ravetta V, et al. (2006) Contrast-enhanced versus conventional and color Doppler sonography for the detection of thrombosis of the portal and hepatic venous systems. AJR Am J Roentgenol 186:763–773CrossRefPubMed

26.

Sorrentino P, D’Angelo S, Tarantino L, et al. (2009) Contrast-enhanced sonography versus biopsy for the differential diagnosis of thrombosis in hepatocellular carcinoma patients. World J Gastroenterol 15:2245–2251CrossRefPubMedPubMedCentral

27.

Ueno N, Kawamura H, Takahashi H, et al. (2006) Characterization of portal vein thrombus with the use of contrast-enhanced sonography. J Ultrasound Med 25:1147–1152PubMed

28.

Tarantino L, Francica G, Sordelli I, et al. (2006) Diagnosis of benign and malignant portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma: color Doppler US, contrast-enhanced US, and fine-needle biopsy. Abdom Imaging 31:537–544CrossRefPubMed

29.

Reynolds AR, Furlan A, Fetzer DT, et al. (2015) Infiltrative hepatocellular carcinoma: what radiologists need to know. Radiographics 35:371–386CrossRefPubMed

30.

Tirumani SH, Shanbhogue AK, Vikram R, Prasad SR, Menias CO (2014) Imaging of the porta hepatis: spectrum of disease. Radiographics 34:73–92CrossRefPubMed

31.

Imaeda T, Yamawaki Y, Hirota K, et al. (1989) Tumor thrombus in the branches of the distal portal vein: CT demonstration. J Comput Assist Tomogr 13:262–268CrossRefPubMed

32.

Tublin ME, Dodd GD 3rd, Baron RL (1997) Benign and malignant portal vein thrombosis: differentiation by CT characteristics. AJR Am J Roentgenol 168:719–723CrossRefPubMed

33.

Mathieu D, Grenier P, Larde D, Vasile N (1984) Portal vein involvement in hepatocellular carcinoma: dynamic CT features. Radiology 152:127–132CrossRefPubMed

34.

McBride K, Masterson J (1992) The thread and streak sign of portal vein tumour thrombus demonstrated by colour Doppler imaging. Br J Radiol 65:607–609CrossRefPubMed

35.

Willatt JM, Hussain HK, Adusumilli S, Marrero JA (2008) MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 247:311–330CrossRefPubMed

36.

Catalano OA, Choy G, Zhu A, Hahn PF, Sahani DV (2010) Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging. Radiology 254:154–162CrossRefPubMed

37.

Li C, Hu J, Zhou D, et al. (2014) Differentiation of bland from neoplastic thrombus of the portal vein in patients with hepatocellular carcinoma: application of susceptibility-weighted MR imaging. BMC Cancer 14:590CrossRefPubMedPubMedCentral

38.

Gouw AS, Balabaud C, Kusano H, et al. (2011) Markers for microvascular invasion in hepatocellular carcinoma: where do we stand? Liver Transpl 17(Suppl 2):S72–S80CrossRefPubMed

39.

Sumie S, Kuromatsu R, Okuda K, et al. (2008) Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol 15:1375–1382CrossRefPubMed

40.

Nishie A, Yoshimitsu K, Irie H, et al. (2009) Radiological detectability of minute hepatic venous invasion in hepatocellular carcinoma. Eur J Radiol 70:517–524CrossRefPubMed

41.

Nishie A, Yoshimitsu K, Asayama Y, et al. (2008) Radiologic detectability of minute portal venous invasion in hepatocellular carcinoma. AJR Am J Roentgenol 190:81–87CrossRefPubMed

42.

Robinson E, Chandarana H, Droxhinin L, et al. (2009) MRI features of HCC do not predict microvascular invasion in liver transplant for hepatocellular carcinoma [abstract]. Liver Transpl 15(suppl 7):S111

43.

Chandarana H, Robinson E, Hajdu CH, et al. (2011) Microvascular invasion in hepatocellular carcinoma: is it predictable with pretransplant MRI? AJR Am J Roentgenol 196:1083–1089CrossRefPubMed

44.

Kim H, Park MS, Choi JY, et al. (2009) Can microvessel invasion of hepatocellular carcinoma be predicted by pre-operative MRI? Eur Radiol 19:1744–1751CrossRefPubMed

45.

Renzulli M, Brocchi S, Cucchetti A, et al (2015) Can current preoperative imaging be used to detect microvascular invasion of hepatocellular carcinoma? Radiology 150998

46.

Ariizumi S, Kitagawa K, Kotera Y, et al. (2011) A non-smooth tumor margin in the hepatobiliary phase of gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance imaging predicts microscopic portal vein invasion, intrahepatic metastasis, and early recurrence after hepatectomy in patients with hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 18:575–585CrossRefPubMed

47.

Kim KA, Kim MJ, Jeon HM, et al. (2012) Prediction of microvascular invasion of hepatocellular carcinoma: usefulness of peritumoral hypointensity seen on gadoxetate disodium-enhanced hepatobiliary phase images. J Magn Reson Imaging 35:629–634CrossRefPubMed

48.

Kim MJ, Lee M, Choi JY, Park YN (2012) Imaging features of small hepatocellular carcinomas with microvascular invasion on gadoxetic acid-enhanced MR imaging. Eur J Radiol 81:2507–2512CrossRefPubMed

49.

Vauthey JN, Dixon E, Abdalla EK, et al. (2010) Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford) 12:289–299CrossRef

50.

Zhang T, Huang JW, Bai YN, Wu H, Zeng Y (2014) Recurrence and survivals following hepatic resection for hepatocellular carcinoma with major portal/hepatic vein tumor thrombus. Hepatol Res 44:761–768CrossRefPubMed

51.

Klein J, Dawson LA (2013) Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. Int J Radiat Oncol Biol Phys 87:22–32CrossRefPubMed

52.

Zhu K, Chen J, Lai L, et al. (2014) Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib—a retrospective controlled study. Radiology 272:284–293CrossRefPubMed

53.

Llovet JM, Ricci S, Mazzaferro V, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390CrossRefPubMed

54.

Llovet JM, Villanueva A, Lachenmayer A, Finn RS (2015) Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol 12:436CrossRefPubMed

55.

Xue TC, Xie XY, Zhang L, et al. (2013) Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. BMC Gastroenterol 13:60CrossRefPubMedPubMedCentral

56.

Kim KM, Kim JH, Park IS, et al. (2009) Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol 24:806–814CrossRefPubMed

57.

Pinter M, Hucke F, Graziadei I, et al. (2012) Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology 263:590–599CrossRefPubMed

58.

Georgiades CS, Hong K, D’Angelo M, Geschwind JF (2005) Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 16:1653–1659CrossRefPubMed

59.

Chung GE, Lee JH, Kim HY, et al. (2011) Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 258:627–634CrossRefPubMed

60.

Kooby DA, Egnatashvili V, Srinivasan S, et al. (2010) Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 21:224–230CrossRefPubMed

61.

Lance C, McLennan G, Obuchowski N, et al. (2011) Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 22:1697–1705CrossRefPubMed

62.

Tsai AL, Burke CT, Kennedy AS, et al. (2010) Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 21:1377–1384CrossRefPubMedPubMedCentral

63.

Poon RT, Cheung TT, Kwok PC, et al. (2015) Hong Kong consensus recommendations on the management of hepatocellular carcinoma. Liver Cancer 4:51–69CrossRefPubMedPubMedCentral

64.

Camacho JC, Moncayo V, Kokabi N, et al. (2015) Y90 radioembolization: multimodality imaging pattern approach with angiographic correlation for optimized target therapy delivery. Radiographics 35:1602–1618CrossRefPubMed

65.

Kulik LM, Carr BI, Mulcahy MF, et al. (2008) Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47:71–81CrossRefPubMed

66.

Inarrairaegui M, Thurston KG, Bilbao JI, et al. (2010) Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 21:1205–1212CrossRefPubMed

67.

Efficacy evaluation of TheraSphere in patients with inoperable liver cancer (STOP-HCC). Available from: https://www.clinicaltrials.gov/ct2/show/NCT01556490. Accessed on 9.12.2015

68.

National Comprehensive Cancer Network Guidelines for Hepatocellular Carcinoma (Version 2.2015) [Accessed on June 30, 2015]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf

69.

Shi J, Lai EC, Li N, et al. (2011) A new classification for hepatocellular carcinoma with portal vein tumor thrombus. J Hepatobiliary Pancreat Sci 18:74–80CrossRefPubMed

70.

Shin DS, Ingraham CR, Dighe MK, et al. (2014) Surgical resection of a malignant liver lesion: what the surgeon wants the radiologist to know. AJR Am J Roentgenol 203:W21–W33CrossRefPubMed

71.

May BJ, Talenfeld AD, Madoff DC (2013) Update on portal vein embolization: evidence-based outcomes, controversies, and novel strategies. J Vasc Interv Radiol 24:241–254CrossRefPubMed

72.

Vennarecci G, Laurenzi A, Santoro R, et al. (2014) The ALPPS procedure: a surgical option for hepatocellular carcinoma with major vascular invasion. World J Surg 38:1498–1503CrossRefPubMed

73.

Schnitzbauer AA, Lang SA, Goessmann H, et al. (2012) Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg 255:405–414CrossRefPubMed

74.

Neeman Z, Libutti SK, Patti JW, Wood BJ (2003) Percutaneous radiofrequency ablation of hepatocellular carcinoma in the presence of portal vein thrombosis. Clin Imaging 27:417–420CrossRefPubMedPubMedCentral

75.

Bujold A, Massey CA, Kim JJ, et al. (2013) Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 31:1631–1639CrossRefPubMed

76.

Li D, Kang J, Golas BJ, Yeung VW, Madoff DC (2014) Minimally invasive local therapies for liver cancer. Cancer Biol Med 11:217–236PubMedPubMedCentral

77.

Hong TS (2013) Radiotherapy for hepatocellular carcinoma with tumor vascular thrombus: ready for prime time? J Clin Oncol 31:1619–1620CrossRefPubMed

78.

University of Texas MD Anderson Cancer Center. Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma. NLM Identifier: NCT01900002 [Accessed on July 20, 2015]. Available from: https://clinicaltrials.gov/ct2/show/NCT01900002

79.

Radiation therapy oncology group. Sorafenib tosylate with or without stereotactic body radiation therapy in treating patients with liver cancer. NLM Identifier: NCT01730937 [Accessed on July 20, 2015]. Available from: https://clinicaltrials.gov/ct2/show/NCT01730937

Title: Clinical implications for imaging of vascular invasion in hepatocellular carcinoma
Authors: Akshay D. Baheti
Gregor M. Dunham
Christopher R. Ingraham
Mariam Moshiri
Chandana Lall
James O. Park
David Li
Douglas S. Katz
David C. Madoff
Puneet Bhargava
Publication date: 01-09-2016
Publisher: Springer US
Published in: Abdominal Radiology / Issue 9/2016
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-016-0763-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Clinical implications for imaging of vascular invasion in hepatocellular carcinoma

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2016

A case of polypoid endometriosis with malignant transformation

Colorectal cancer mimics: a review of the usual suspects with pathology correlation

MR findings of Lynch syndrome-related uterine endometrial carcinoma: a case report

Superselective transcatheter arterial embolization in patients with acute peripancreatic bleeding complications: review of 44 cases

Single-session alcohol sclerotherapy of symptomatic liver cysts using 10–20 min of ethanol exposure: no recurrence at 2–16 years of follow-up

Primary hepatic neuroendocrine tumors: clinical characteristics and imaging features on contrast-enhanced ultrasound and computed tomography

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page